215 related articles for article (PubMed ID: 1814896)
1. Iron chelation.
Chandy M
J Assoc Physicians India; 1991 Sep; 39(9):665-6. PubMed ID: 1814896
[No Abstract] [Full Text] [Related]
2. Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis.
Nijjar PS; Vongooru H; Tamene A; Valeti U; Masri C
Minn Med; 2015 Jul; 98(7):47. PubMed ID: 26267924
[No Abstract] [Full Text] [Related]
3. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.
Agarwal MB; Gupte SS; Vasandani D; Viswanathan C; Puniyani RR; Ramanathan J; Massil DE; Shah S; Rajyadhyaksha GC; Bhave AA
J Assoc Physicians India; 1991 Sep; 39(9):669-72. PubMed ID: 1814897
[TBL] [Abstract][Full Text] [Related]
5. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
6. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.
Olivieri NF; Koren G; St Louis P; Freedman MH; McClelland RA; Templeton DM
Semin Hematol; 1990 Apr; 27(2):101-4. PubMed ID: 2190316
[No Abstract] [Full Text] [Related]
7. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
[No Abstract] [Full Text] [Related]
8. Oral iron chelators.
Nathan DG; Piomelli S
Semin Hematol; 1990 Apr; 27(2):83-5. PubMed ID: 2190320
[No Abstract] [Full Text] [Related]
9. Clinical studies on iron chelation in patients with thalassemia major.
Freedman MH; Olivieri N; Benson L; Liu P; McClelland R; St Louis P; Templeton D; Koren G
Haematologica; 1990; 75 Suppl 5():74-83. PubMed ID: 2086384
[No Abstract] [Full Text] [Related]
10. Advances in the use of iron-chelating agents for the treatment of iron overload.
Modell B
Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
[No Abstract] [Full Text] [Related]
11. [Iron-chelating treatment].
Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
[No Abstract] [Full Text] [Related]
12. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
13. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
[TBL] [Abstract][Full Text] [Related]
14. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
[No Abstract] [Full Text] [Related]
15. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
16. An update on disordered iron metabolism and iron overload.
Ward R
Hematology; 2010 Oct; 15(5):311-7. PubMed ID: 20863426
[TBL] [Abstract][Full Text] [Related]
17. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
18. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Kolnagou A; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
[TBL] [Abstract][Full Text] [Related]
19. Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridines.
Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV
Prog Clin Biol Res; 1989; 309():107-14. PubMed ID: 2780745
[No Abstract] [Full Text] [Related]
20. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Fischer R; Piga A; Harmatz P; Nielsen P
Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
